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Mouse cytomegalovirus (MCMV), a β-
herpesvirus that establishes latent and 
persistent infections in mice, is a valuable 
model for studying complex virus-host 
interactions. MCMV encodes the m145 family 
of putative immunoevasins with predicted 
MHC-I structure. Functions attributed to some 
family members include downregulation of host 
MHC-I (m152) and NKG2D ligands (m145, 
m152, m155) and interaction with inhibitory or 
activating NK receptors (m157). We present the 
cellular, biochemical and structural 
characterization of m153, which is a heavily 
glycosylated homodimer, that does not require 
β2m or peptide, and is expressed at the surface 
of MCMV-infected cells. Its 2.4 Å crystal 
structure confirms that this compact molecule 
preserves an MHC-I-like fold and reveals a 
novel mode of dimerization, confirmed by site-
directed mutagenesis, and a distinctive 
disulfide-stabilized extended amino terminus.  
The structure provides a useful framework for 
comparative analysis of the divergent members 
of the m145 family. 
 
A major strategy for immune evasion, 
employed by the large DNA viruses like herpes- 
and poxviruses, is the expression of a variety of 
molecules that attenuate the host’s immune 
response.  Some of these impair the cellular 
pathways of antigen processing and presentation, 
while others serve as decoys, mimicking host 
molecules crucial to natural killer (NK) or T cell 
recognition (1). The genome of MCMV, which 
serves as a model for the human virus (HCMV), 
encodes a set of proteins that are predicted to be 
structural analogs of class I major 
histocompatibility (MHC-I) glycoproteins (2-4).  
The detailed function of each of these viral MHC-
I-like molecules (MHC-Iv) has not yet been 
determined, but several examples suggest that they 
either downregulate host MHC-I or MHC-I-like 
molecules or directly bind to NK cell inhibitory 
receptors.  Thus, they can interfere with key 
components of T cell recognition or NK cell 
activation, thereby promoting virus survival. 
MHC-I molecules, transmembrane cell surface 
receptors consisting of a heavy chain, a β2-
microglobulin (β2m) light chain, and bound 
peptides, are poised for recognition by clonotypic 
αβ receptors on CD8+ T cells or by inhibitory or 
activating receptors on NK cells.  MHC-I are 
classical (Ia) or non-classical (Ib) molecules based 
on their amino acid sequence polymorphism, 
function, and tissue-specific expression.  The 
heavy chain consists of an α1α2 domain unit 
containing two α-helices set atop an eight-
stranded β-sheet platform and an Ig-like α3 
domain (5).  MHC-Ib molecules exhibit less 
polymorphism, most do not bind peptide, and they 
vary in their association with β2m (6). MHC-Ib 
proteins function both in immune recognition and 
in other physiological settings (7).    
Only one MCMV protein, m144, like its 
HCMV counterpart UL18 (8), is clearly related to 
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MHC-I based on amino acid sequence similarity 
(9). m144 allows virus-infected cells to evade the 
NK cell response, but its mechanism of action and 
the nature of any ligand remain unclear. 
Expression studies of m144 indicate that, unlike 
MHC-Ia molecules, it does not require peptide for 
cell surface expression (10,11). The crystal 
structure of m144 reveals an MHC-I-like protein, 
bound to β2m but not associated with peptide, 
confirming predictions based on sequence 
comparison. The molecule is characterized by a 
large angle between α1α2 and α3, a unique 
stabilizing disulfide bond in α1α2, and relatively 
loose association of the heavy chain with β2m 
(11). 
 In addition to m144, MCMV encodes the 
eight molecules of the m145 family, all of which 
are predicted to have an MHC-I protein fold (2-4), 
despite the lack of significant sequence similarity 
to m144 or to MHC-Ia molecules. Four of the 
family members (m145, m152, m155, and m157) 
function as immunoevasins. m145, m152 and 
m155 downregulate the cell surface expression of 
ligands of the activating receptor NKG2D (12-15). 
m152 also causes the retention of MHC-I 
molecules in the endoplasmic reticulum-Golgi 
intermediate compartment (16). m157 functions by 
binding the NK inhibitory receptor Ly49I129 in 
MCMV sensitive mouse strains such as 129.  
Alternatively it can interact with the NK activating 
receptor Ly49H in strains (e.g. C57BL/6) that are 
resistant to MCMV infection (2,17). m157 
expression does not require either β2m or peptide 
(2). Its crystal structure revealed several deviations 
from the MHC-Ia fold:  an extended, helical N-
terminus, designated α0, that precedes the 
canonical α1 helix and imparts a three-helix 
structure to the amino terminal α1α2 domain; a 
long α2 helix that extends into the α3 domain; 
short interhelical distances and close interactions 
of the α1α2 domain with α3 resulting in a 
molecule significantly more compact than 
classical MHC-I; and an α3 domain whose Ig fold 
is less twisted than typical Ig folds (18).  
The unique functions of m145, m152, m155, 
and m157 suggest that each member of the m145 
family is important in modulating the response of 
the host to MCMV infection.  The structural 
features of m144 and m157 imply that other 
members of the m145 family also may have 
evolved significant structural deviations from 
typical MHC-I to solve novel difficulties in their 
encounter with the immune system.  An 
understanding of the evolution and function of the 
MHC-I-like molecules of MCMV demands 
examination of the cellular expression, 
immunological function, and molecular structure 
of each of these molecules.  To gain further insight 
into another member of the m145 family, we have 
examined m153 in detail.  We first demonstrate 
that m153 is a functional gene that directs the 
expression of its encoded protein to the surface of 
MCMV-infected cells.  Surface expression is 
independent of the transporter associated with 
antigen processing (TAP) or β2m.  In surprising 
contrast to MHC-I molecules, recombinant soluble 
m153 is homodimeric. The crystal structure of 
m153 described here reveals the mode of 
dimerization in addition to other distinguishing 
features. Thus, although prediction algorithms 
group members of the m145 family together 
within the broad MHC-I structural family, the 
details of the individual structures show wide 
variation from MHC-I and demonstrate the 
robustness and adaptability of the MHC-I fold in 
the service of diverse biological functions.  
 
EXPERIMENTAL PROCEDURES 
 
Cell lines - NIH3T3, RMA and RMA-S were 
grown in DMEM containing 10% fetal bovine 
serum, 5 x 10-5 M 2-mercaptoethanol, 1x non-
essential amino acids (Biowhittaker) and 50 µg/ml 
gentamicin at 37°C in 5% CO2. R1.1 and R1E 
were cultured in RPMI containing the same 
supplements as above. Drosophila S2 cells were 
maintained in Insect Express medium 
(BioWhittaker) supplemented with 50 µg/ml 
gentamicin except where mentioned otherwise.  
Antibodies - Rabbit antiserum was produced 
against m153 expressed as inclusion bodies in E. 
coli. Reduced, denatured SDS-gel purified m153 
was emulsified in complete Freund adjuvant prior 
to immunization. The mouse monoclonal antibody 
mAb153.16 was generated with the extracellular 
domain of mature m153 (amino acids 1-314) 
expressed in S2 cells and stains m153 transfected 
cells and immunoprecipitates m153 from 
transfected or virus-infected cells.  
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Vector constructs – Insect cell expression - 
cDNA encoding the extracellular domain of the 
mature form of m153 (amino acids 1-314) was 
PCR-amplified from MCMV-infected cell culture 
supernatants (Smith strain – American Type 
Culture Collection, catalog no. VR-1399) using 
primers 5’GGATCCGAGGTCGTGCGGCCCGAA-
GTTAAC and 5’GGTACCTCAATGGTGATGGT-
GATGATGGCTGCCGCGCGGCACCAGGGTCAGT
CTCGAATCGTTGATCGTC. A BamHI restriction 
site was incorporated in the forward primer and a 
thrombin cleavage site (LVPRG), a 6xHis tag, a 
termination codon, and a KpnI restriction site were 
incorporated in the reverse primer. The m153 PCR 
product was directly cloned into the pCR4-Topo-
TA vector (Invitrogen), the sequence verified, and 
then the excised BamHI/KpnI m153 fragment was 
inserted in the BglII and KpnI sites of pMT-Bip-
V5-His (Invitrogen). 
Mammalian cell expression - The full-length 
m153 gene (amino acids -22-382, including the 
signal peptide sequence) was amplified from 
MCMV infected cell culture supernatants and an 
N-terminal FLAG-tag introduced by sequential 
PCR. The sequential forward primers used were  
A-5’TCAGCGGAGGTCGACTACAAGGATGACGA-
TGACAAGGTGCGGCCCGAAGTTAACAGG 
B-5’TTGGTTCTCATCTCAGGAGGGTTCTGGGC-
GTGCGGCTCAGCGGAGGTCGACTACAAG 
C-5’GCTACGGGATCCATGATTCCCCTTCTCCTTC-
TGCCGTTGGTTCTCATCTCAGGAGGG,  
and the reverse primer was 5’TACGCTGAATTC-
TTACACCACATTCTCCTCCGTATCCGAGCA.             
5’ BamHI and a 3’ EcoRI restriction sites were 
incorporated in the forward and reverse primers 
respectively for subsequent cloning into the        
pIRES-hr-GFP-II vector (Stratagene). 
BiFC vectors - Mammalian expression 
vectors encoding the N-terminal 1-154 residues 
(N-YFP) or the C-terminal 155-238 residues (C-
YFP) of YFP were a kind gift from Dr. K. Ozato, 
NICHD, NIH. m153 and m144 were amplified 
from existing full-length constructs using primers 
m153_5YFP 5’ACGGGATCCATGATTCCCCTTCT-
CCTTCTGCCG and m153_3YFP 5’ACGGAA-
TTCGCCACCACATTCTCCTCCGTATCCG and 
m144 was amplified using primers m144_5YFP 
5’ACGAGATCTATGAGGGCTCTGGCGCTG and 
m144_3YFP 5’ACGGAATTCGCAATGCTGGG-
ATCCGGGACCGTG. The PCR products were 
digested and inserted in the BglII and EcoRI sites 
of N-YFP and C-YFP and the sequences verified. 
The resulting constructs encode fusion proteins of 
m153 and m144 linked at their C-termini to either 
the N- or C-terminal fragments of YFP. A 12-13 
amino acid spacer separates the viral proteins from 
the YFP fragments. 
β2m and TAP-dependence - The Amaxa 
nucleofector (Amaxa Biosystems) was used to 
introduce the pIRES-hr-GFP II vector (Stratagene) 
encoding either FLAG-m153 or H-2Dd into R1.1 
and R1E cells (solution V, program A30) or into 
RMA and RMA-S cells (solution T, program A30) 
according to the manufacturer’s instructions. 18-
24 hours post transfection the cells were stained 
for surface expression of FLAG-tagged m153 with 
the M2 monoclonal antibody (Sigma) and a PE 
labeled anti-mouse IgG1 antibody (Southern 
Biotech). H-2Dd was detected using the PE-labeled 
34-5-8S antibody (BD Biosciences). Cells were 
analyzed by flow cytometry (FACSCalibur, BD 
Biosciences). 
MCMV infection, cell surface staining and 
FACS - 70% confluent NIH3T3 cells were 
infected with MCMV-GFP (a virus containing 
GFP at an innocuous site (19)) at an m.o.i. of two. 
Twenty-four hours post infection (p.i.) the cells 
were detached with a non-enzymatic cell 
dissociation solution (Cellstripper, Cellgro) and 
resuspended in PBS containing 5% FCS and 0.1% 
NaN3. F(ab’)2 fragments were generated from 
monoclonal antibody mAb153.16 with the 
Immunopure IgG1 F(ab’)2 kit (Pierce). Infected 
and uninfected cells were incubated with the 
F(ab’)2 followed by anti-mouse IgG-APC. Dead 
cells were excluded by propidium iodide gating. 
Cells were analyzed with a FACSCalibur and 
virus-infected cells were gated on GFP expression.  
Bimolecular fluorescence complementation 
(BiFC) - NIH3T3 cells were transfected with 153-
N-YFP and 153-C-YFP or 144-N-YFP and 144-C-
YFP using the Amaxa nucleofector (solution R, 
program U30). Cells were then seeded on 
chambered coverslides and incubated for 48 hours 
at 37 °C. A Leica TCS AOBS SP2 confocal 
microscope (Leica Microsystems) equipped with a 
63x 1.4 NA PL APO objective was used to 
examine live cells at room temperature for YFP 
fluorescence complementation. Leica TCS 
v2.1547 software was used to capture the images. 
After analysis the cells were detached with trypsin 
and the YFP positive cells were quantified by flow 
cytometry.  
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Immunoprecipitation and western blots - 
Transiently transfected and virus-infected cell 
lines were processed for immunoprecipitation and 
western blotting as detailed in the supplementary 
Experimental Procedures.  
Expression and purification of m153 in S2 
cells - The pMT-Bip-m153-His construct together 
with puromycin and blasticidin resistance- 
encoding plasmids (10:1:1 ratio by weight) were 
transfected into S2 cells using Fugene6 (Roche) 
according to the manufacturer’s protocol. 48 hours 
after transfection the cells were transferred to 
selective medium containing 5 µg/ml puromycin 
(Sigma) and 5 µg/ml blasticidin (Calbiochem). 
Resistant cells were maintained in selective 
medium in shaker cultures (28 °C, 100 rpm). 
Expression of m153 was induced with 1 mM 
CuSO4 at a cell density of 2 x 10
7 /ml. m153 was 
purified on a Ni-NTA column (Qiagen) and then 
subjected to SEC (Shodex KW802.5 or Pharmacia 
Superdex 75). The His-tag was removed by 
thrombin cleavage at 37 °C for 2h, and the protein 
was purified by anion exchange chromatography 
(Mono Q, Pharmacia). For preparation of a 
selenomethionine (SeMet) derivative of m153, the 
m153/S2 cells were grown in Orbigen insect cell 
medium to 2 x 107 cells/ml. The cells were then 
washed in methionine-free medium (Orbigen) and 
starved in this medium for 6 hours under normal 
growth conditions. Protein expression was induced 
by simultaneous addition of 1 mM CuSO4 and 60 
µg/ml SeMet (Sigma). The SeMet labeled protein 
was purified as described for the native protein.  
Crystallization, structure determination and 
refinement – Crystals of the SeMet derivative of 
m153 were grown in hanging drops at 18ºC over 
25% PEG 2000 MME, 0.1 M TRIS-HCl pH8 
(Solution 24, The PEGs Suite, Qiagen). Addition 
of 0.5% β-D-maltoside to the drops yielded 
crystals that diffracted to 2.3 Å. Diffraction data 
for SAD phasing were collected on a single crystal 
on beamline X29A at the NSLS, Brookhaven, at a 
wavelength of 0.9791 Å and processed with 
HKL2000 (20). The automated 
SOLVE/RESOLVE scripts as incorporated in the 
AutoSol module of the PHENIX suite (21) were 
used with data truncated at 2.8 Å to obtain SAD 
phases followed by automated model building and 
docking to the m153 sequence. Ambiguously 
placed residues were rebuilt manually into the 
SAD-phased map in Coot as alanines (22).  To 
extend the resolution to 2.4 Å a molecular 
replacement search was carried out in Phaser (23) 
with the partially built model yielding Z-scores of 
11.0 and 23.7 for the rotation and translation 
functions, respectively, for one dimer in the 
asymmetric unit. Rigid body refinement specifying 
α1α2 and α3 as separate domains yielded a model 
with initial R and Rfree of 36.9% and 38.6% 
respectively. Refinement at 2.4 Å was continued 
in Refmac5 (24) with tight NCS restraints between 
chains A and B with further model building guided 
by 2Fo-Fc and Fo-Fc maps generated in Coot. 
Although data were collected to 2.3 Å, data in the 
2.38-2.3 shell were of insufficient quality and 
completeness. Therefore only data to 2.4 Å were 
used in refinement. Residues in the 231-237 loop 
which had little or no electron density were 
omitted from the NCS restraints. Optimal domains 
for TLS refinement were identified and input files 
for TLS refinement were generated using the 
TLSMD web server (25). TLS refinement using 10 
TLS groups per chain decreased Rfree from 29.9% 
to 28%. Finally, waters were added with CNS (26) 
and a final round of refinement was performed 
without NCS restraints. The final model has 
Rcryst=23% and Rfree=27.9%, includes residues 2-
230 and 238-277 of chain A and residues 5-277 of 
chain B and has 57 waters. The atomic coordinates 
and structure factors have been deposited in the 
Protein Data Bank (27) under accession number 
2O5N. Buried surface area calculations were 
performed in CNS. Figures were generated using 
PyMOL (28). 
Hinge angles were calculated using HINGE, a 
program written by Peter Sun. HINGE calculates 
an ellipsoid (defined by axes a, b and c) for each 
indicated domain, and reports the angle between 
the long axes of the adjacent domains as the hinge 
angle. HINGE is available at: 
http://sis.niaid.nih.gov/programs/hinge.html.  
Transient expression of wild type and mutant 
m153 in SF9 cells – Alanine mutations were 
introduced simultaneously at four residues (T128, 
S131, R225 and S241) in the m153-N-YFP 
construct using the QuickChange Multi 
mutagenesis kit (Stratagene). Wild type and 
mutated m153 (residues -22-314) genes were 
PCR-amplified from the m153-N-YFP and m153-
N-YFP-mutant constructs using primers 
5’CGTCACCCATGGCAATTCCCCTTCTCCTTCTG
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CCGTTGGTTCTC and 5’ACTTCGCTCGAGGGT-
GAGTCTCGAATCGTTGATCGTCCTCTG.  The 
PCR products were digested with NcoI and XhoI 
and inserted into the corresponding sites of the 
pIEx-4 SF9 expression vector (Novagen). 200 µg 
of m153-pIEx-4 or quadruple mutant-m153-pIEx-
4 were transfected into 1 x 108 exponentially 
growing SF9 cells in 100 ml with 1ml of Insect 
GeneJuice transfection reagent (Novagen).  72h 
after transfection the cell supernatants were 
collected.  Wild type and quadruple mutant m153 
were then purified on Ni-NTA and SEC columns 
as described for S2 insect cell expression.  
Analytical ultracentrifugation –
Sedimentation velocity experiments were 
conducted with a ProteomeLab XLI 
ultracentrifuge (Beckman Coulter). 400 µl samples 
were loaded at concentrations of 0.3 mg/ml for 
m153 wild type and 0.5 and 0.1 mg/ml for the 
m153 mutant and centrifuged at 50,000 rpm at 
20°C.  Sedimentation data were acquired with the 
Rayleigh interference optical system at 1 min 
intervals, and data were analyzed using SEDFIT 
software (29). Additional details on experimental 
and data analysis protocols can be found at 
http://www.analyticalultracentrifugation.com. 
 
RESULTS 
 
m153 is expressed on the surface of MCMV-
infected fibroblasts – The open reading frame of 
the m153 gene predicts a type I transmembrane 
glycoprotein with a core molecular weight of 45 
kDa. As a first step in the functional 
characterization of m153, we examined its 
expression in MCMV-infected fibroblasts. 
NIH3T3 cells, infected with MCMV at an m.o.i. of 
2, expressed readily detectable levels of m153 at 
the cell surface 24h p.i. as detected by the 
monoclonal antibody mAb153.16, specific for the 
extracellular domain of m153 (Fig. 1A). 
Uninfected cells did not stain with this antibody. 
By immunoprecipitation m153 was detected in 
lysates of infected cells as early as 3 and up to 48 
hours after infection with protein levels peaking at 
24 hours p.i. (data not shown). 
Immunoprecipitation of cell lysates followed by 
SDS-PAGE and western blot analysis of m153 
revealed an unexpectedly high apparent molecular 
weight of 80 kDa, which is decreased to 45 kDa 
upon deglycosylation with PNGaseF (Fig. 1B). 
Such heavy glycosylation is consistent with six 
predicted sites for asparaginyl-carbohydrate 
addition. 
Cell surface expression of m153 is 
independent of β2m or TAP expression – Since the 
MHC-I fold was predicted for all members of the 
MCMV m145 family (4), we next determined 
whether m153 shares the requirements of classical 
MHC-I molecules for β2m and peptide for stable 
expression. To investigate its requirement for β2m 
we transfected N-terminally FLAG-tagged m153 
(FLAG-m153) into a cell line deficient in β2m 
(R1E (30)) as well as its β2m sufficient 
counterpart (R1.1). m153 surface expression was 
equivalent in both cell types indicating that m153 
does not require β2m for stable surface expression 
(Fig. 1C).  
 To evaluate the requirement for bound 
peptide we examined surface expression of m153 
in RMA-S, a TAP deficient cell line that fails to 
transfer peptides from the cytosol to the ER (31). 
MHC-Ia molecules expressed in such cells are 
unstable at the cell surface. We transfected RMA-
S and RMA (TAP+) cells with FLAG-m153 and 
evaluated surface expression of the viral protein in 
comparison to transfected H-2Dd, an MHC-Ia 
molecule (Fig. 1D). TAP deficiency had no effect 
on m153 surface expression, whereas expression 
of H-2Dd was clearly reduced.  We conclude that 
m153 does not require β2m or bound peptide for 
stable surface expression.  
The MHC-I fold of m153 – To elucidate the 
structure of m153 a SeMet derivative was 
prepared by biosynthetic labeling of the protein 
expressed in Drosophila S2 cells. Size exclusion 
chromatography indicated that soluble m153 was a 
dimer (Fig. S1). Diffraction data from a single 
crystal were collected, the structure was solved by 
SAD phasing, and the model was refined at 2.4 Å 
resolution to final Rcryst and Rfree of 23 and 27.9 
respectively (Table 1). There is a single dimer in 
the asymmetric unit with chains designated A and 
B. We observed continuous electron density for 
residues 2-230 and 238-277 of chain A and 
residues 5-277 of chain B. No electron density was 
observed for the C-terminal residues 278-314 of 
either chain and these were omitted from the 
model. The average B-factor was 42 Å2 for chain 
A and 32 Å2 for chain B. We selected chain B to 
describe the structural features of the monomer as 
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 6 
they relate to the MHC-I fold because it is more 
complete and has lower B-factors.  
 The structure of m153 (Fig. 2) reveals basic 
structural elements of the MHC-I fold. The m153 
α1α2 domain consists of a unit in which the α1 
helix and a discontinuous α2 helix rest atop a 
platform of seven β-strands. Three of the strands 
derive from the α1 domain and four from α2.  The 
fourth β−strand of the α1 domain, commonly 
found in MHC-Ia and Ib molecules, is not 
observed in m153. Unlike either MHC-Ia or Ib 
molecules the C-terminal end of the α2-helix 
extends downwards into a third helix (designated 
H2b) that connects the α1α2 domain with the Ig-
like α3 domain (Fig. 2A).  
 Several structural features of the m153 
monomer differ substantially from classical MHC-
I molecules.  Most striking is the N-terminus, 
extended by 20 residues, that starts adjacent to the 
G strand of the α3 domain, forming a short β 
strand. From there it extends upwards alongside 
the H2b helix and continues as the first strand of 
the platform beginning at residue 21 (Fig. 2A). 
This feature is absent in all MHC-I molecules 
described thus far and differs substantially from 
m157, whose extended N-terminus forms instead a 
third, short helix adjacent to the α2 helix (Fig. 3A 
& 3C). A unique disulfide between C16 and C171 
anchors the extended N-terminus of m153 to the 
H2b helix (Fig. 2D). In addition several hydrogen 
bonds link the extended N-terminal strand 
(residues 6-15) and the loop between platform 
strands β2 and β3. Other hydrogen bonds link the 
extended N-terminus to the H2b helix and the α3 
F-G loop and serve to further stabilize the 
structure (Fig. 2C). The α1 and α2 helices are 
shorter than those observed in MHC-Ia proteins 
and are closely juxtaposed above the β sheet floor. 
Close interactions between these helices preclude 
the binding of peptide or other ligand (Fig. 2B), in 
agreement with cellular expression studies 
indicating that m153 does not depend on bound 
peptide for stability (Fig. 1D). The platform is 
stabilized by a second unusual disulfide  (C101-
C108) which connects strands β5’ and β6’ of the 
floor (Fig. 2D). A similar bond is seen in m157 
(C103-C112) but MHC-Ia molecules preserve a 
disulfide bond in the same region which links β-
strand 5 of the platform to the α2 helix (C101-
C164) (32). The presence of the unusual disulfide 
bonds in m153 was confirmed by mass 
spectrometry (Figs. S3 & S4). 
 The α3 domain of m153 has a C2 type Ig-
fold, which is characterized by a more compact 
domain and shorter intercysteine spacing than the 
C1 or V type fold (33). The A, B and E strands 
make up one sheet of the domain and the C, C’, F 
and G strands make up the opposite sheet (Figure 
2A). The canonical Ig-domain disulfide bond 
(C203-C255) connects strands B and F. Searches 
against the DALI database (34) identified m144, 
also with a C2 type Ig-fold, and CD1d as proteins 
with α3 domains that are structurally most closely 
related to m153. The difference between the strand 
dispositions in the α3 domains of m153 and m157 
is indicated by the relatively high rmsd of 2.3 Å 
for the superposition of 67 Cα atoms. The α3 
domain of m153 has longer β-strands that exhibit 
the characteristic β-sandwich twist, whereas the 
m157 α3 domain has strands that are shorter and 
form flatter sheets (Fig. 3C). The terminal residues 
that were modeled in both structures adopt 
different conformations, in m153 they form a short 
α-helix, whereas in m157 the C-terminal strand 
forms a circular loop that contacts both sheets of 
the α3 domain (18). 
 In Figure 3 we compare the α1α2 domain of 
m153 chain B to that of m157, H-2Kb (35), rat 
FcRn (36), and the NKG2D ligand Rae-1β (37). 
The α1 and H2b helices of m153 and m157 are in 
equivalent positions, whereas their α2 helices 
differ. The N-terminal end of the m157 α2 helix 
was not modeled due to lack of electron density 
(18). The m153 α2 helix starts with two full turns 
(residues 140-146), followed by an extended 
region that stretches along the platform ending in 
two turns of helix before bending sharply 
downward to continue as the H2b helix.  
 The maximal distance between the α1 and α2 
helices of m153 is 8.1 Å compared to 16.8 Å in H-
2Kb  (Fig. 3A). Surface representations of the 
α1α2 domains of m153 and H-2Kb (Fig. 3B) 
illustrate the lack of a peptide-binding groove in 
m153. The groove region of m153 is comparable 
to that of Rae-1β and FcRn, two molecules that 
also do not bind peptide. The maximal distance 
between Cα atoms of the α1 and α2 helices of 
Rae-1β and FcRn are 8.2 Å and 9.2 Å 
respectively. The α1 helices of m153, Rae-1β, and 
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FcRn have a similar arrangement on the platform 
but the m153 helix is shorter. The m153 platform 
has seven strands compared to the eight found in 
classical MHC-I proteins (Fig. 3A). 
 The hinge angle between α1α2 and α3 of 
m153 chain B is 76º, which is within the range of 
the MHC-I molecules H-2Kb, CD1d and T22 (71-
74º), but is smaller than that of m157 (81º), MICA 
(116º) and m144 (99º) (Table S1). The m153 α3 
domain makes extensive contacts with the H2b 
helix, with the loop connecting strands β2 and β3 
of the platform as well as with the loop connecting 
β3 and α1. The buried surface area between α1α2 
and α3 of m153 is 1777 Å2, which is considerably 
larger than the analogous interfaces in m157 (1265 
Å2) and H-2Kb (455 Å2).   
The m153 dimer – SEC of the insect cell 
expressed extracellular portion of m153 indicated 
that the molecule formed a stable non-covalent 
homodimer (Fig. S1), an observation confirmed by 
equilibrium and velocity sedimentation (data not 
shown). The crystal structure reveals the details of 
the mode of dimerization. Two MHC-I-like chains 
of m153 are organized in a head-to-tail 
arrangement forming a compact dimer (Fig. 4A). 
The two chains are almost identical (rmsd of 0.624 
Å for superposition over 268 Cα atoms). The 
interaction of the platform domain of one subunit 
with the α3 domain of the other imparts a coronal 
shape forming a central cavity with a volume of 
about 9500 Å3.  The conical cavity measures 46 Å 
x 35 Å at the top narrowing down to 22 Å x 18 Å. 
It is closed off at the bottom where the K115 
sidechains of each subunit are only 4 Å apart. We 
propose an orientation of the m153 dimer with 
respect to the plasma membrane shown in Figure 
4B. The subunits lie with their long axes parallel 
to the membrane and with the α1 helices closest to 
the membrane. In this orientation the C-termini of 
both chains point towards the membrane (Fig. 4B 
– lower). The 37 C-terminal residues for which no 
electron density was observed in either chain may 
form a flexible stalk connecting the ectodomain to 
the transmembrane region. m153 conserves only 
two of the 31 β2m-contacting residues present in 
H-2Kb. It is evident from the dimer orientation of 
m153 that association with β2m would be 
sterically hindered, an observation consistent with 
the β2m independence of m153 expression (Fig. 
1C).  
 Three sugar moieties were modeled in the 
m153 structure (at N107 in chains A and B and 
N252 in chain B). These all point upward from the 
dimer away from the cell surface. Mass 
spectrometry indicated glycosylation at five of the 
six predicted N-linked carbohydrate addition sites 
(data not shown). These sites occur in both α1α2 
and α3, and are distributed around the periphery of 
the m153 dimer, with none in the central cavity or 
at the proposed membrane proximal face of the 
molecule (Fig. 4A). The electrostatic surface of 
the m153 dimer reveals four nearly symmetrical 
basic patches inside the central cavity, and two 
highly acidic regions on the bottom surface that 
are formed by the loop that connects the A and B 
strands of the α3 domain and the C-terminal α-
helical fragment (Fig. 4C). 
 The m153 dimer interface is formed by 
parallel β-strand interactions between the platform 
(β8’ strand) of one subunit and the α3 domain (C’ 
strand) of the second subunit (Fig. 5A), resulting 
in two extended, twisted β-sheets of 12 strands 
each that form the core of the dimer. The two 
interfaces are not perfectly symmetrical as 21 
residues of chain A and 22 residues of chain B are 
involved in dimerization. There are 16 hydrogen 
bonds at the interface, most of which represent 
backbone interactions (Fig. 5B). In addition there 
are 114 non-bonded contacts. The area buried at 
the dimer interface is 1088 Å2 which is larger than 
that observed in HLA-G (676 Å2), which forms a 
disulfide-linked MHC-Ib dimer (Fig. 5C). The 
shape complementarity (Sc) index of the dimer 
was calculated as 0.72, which is higher than that of 
most antibody-antigen interfaces (0.62-0.68), 
consistent with the stability of the homodimer 
(Sc=1 represents a perfect fit, (38)).  To confirm 
the observed interface we tested the effects of 
mutating four interface residues T128, S131, 
R225, and S241, all of which form side-
chain/side-chain hydrogen bonds, to alanine (Fig. 
5C).  Wild type m153 and a mutant containing 
these four alanine mutations were expressed and 
analyzed by ultracentrifugation and SEC. The 
mutant protein had a smaller sedimentation 
coefficient indicating disruption of the dimer (Fig. 
5D). SEC confirmed the smaller size of mutant 
m153 (Fig. S5). Thus the four mutations 
destabilized the m153 dimer and confirm the mode 
of dimerization visualized in the structure.   
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Full-length m153 is dimeric in mammalian 
cells – To exclude the possibility that dimerization 
is a result of the engineering of soluble m153, we 
used two approaches to examine m153 in 
mammalian cells. In BiFC (39) experiments we 
fused full-length m153 to either N- or C-terminal 
segments of YFP.  While transfectants of either 
construct alone did not show fluorescence, co-
transfection of m153-N-YFP and m153-C-YFP 
resulted in the complementation of YFP 
fluorescence in transfected cells (Fig. 6A and Fig. 
S2), indicating that m153 does form dimers. Cells 
transfected with YFP fusion constructs of m144, a 
monomeric MHC-Iv protein, showed fewer than 
1% YFP positive cells. In a second approach we 
co-transfected N-terminal FLAG- and HA-tagged 
m153 in NIH3T3 cells. Successful 
immunoprecipitation of m153 with anti-FLAG 
antibodies and western blot detection with anti-HA 
antibodies confirmed that m153 dimerizes in 
transfected fibroblasts (Fig. 6B). Together these 
results provide strong evidence that m153 is a 
dimer when expressed as the full-length protein in 
mammalian cells.  
Comparison of m153 to the m145 family – 
m153 is related by sequence to proteins of the 
mouse and rat CMV 145 families but has no direct 
homolog in the rat virus (3,40). The m153 protein 
is most closely related to m152 (28% identity), a 
known regulator of MHC-I and NKG2D ligands in 
MCMV-infected cells (14,16). Figure 7 shows a 
sequence alignment of the m145 family 
highlighting shared structural features. Based on 
comparison of m153 and m157 we suggest that the 
core of the viral MHC-I-like fold of the m145 
family is comprised of the α1α2 domain, the 
extended H2b helix and an Ig-like α3 domain. The 
number of platform strands, the length of α2 on 
top of the platform and the position of some 
disulfide bonds may vary. A crucial stabilizing 
interaction for this MHC-I-like fold is that 
between E70 (α1 helix), R166 and W167 (H2b 
helix). Apart from a cysteine in the α3 domain, 
these three residues are the only amino acids that 
are conserved throughout the mouse and rat 145 
families, emphasizing the importance of this salt-
bridge. Within the m145 family stretches of 
similarities are found in α helix and β sheet 
regions, whereas loop regions and the α3 domain 
show less conservation. The m153 residues 
involved in dimerization are not conserved in the 
rest of the family consistent with our observation 
that m151 and m152 do not dimerize in solution 
(unpublished). Thus dimerization may be unique 
to m153.  Five family members contain cysteines 
that align with those of the unusual m153 C16-
C171 disulfide. The C101-C108 and C203-C255 
disulfides are also conserved among some of the 
family members. The limited sequence similarity 
of the N- and C-terminal regions of the 
extracellular domains of the m145 family 
members likely indicate a structural divergence in 
these parts of these molecules.  
 
DISCUSSION 
 
MHC-I molecules play a crucial role in the 
protection of the host against virus infection. Not 
only are MHC-I molecules essential for the 
detection of infection and priming of the cytotoxic 
CD8+ T cell response, but their presence on the 
cell surface protects healthy cells from attack by 
natural killer cells. Viral molecules with an MHC-
I-like structure are likely to be excellent decoys for 
inhibitory natural killer receptors and may be able 
to interact with numerous molecules involved in 
the immune response. It is therefore not surprising 
that herpesviruses have incorporated MHC-I-like 
molecules in their arsenal of immunoevasins. 
Human, mouse and rat CMV encode MHC-I-like 
molecules that exhibit different levels of similarity 
to MHC-Ia molecules (3,40). HCMV encodes the 
MHC-I homolog UL18 which binds both β2m and 
peptide and engages the inhibitory receptor LIR-1 
(41). It also encodes UL142, which functions to 
inhibit NK cell lysis, has less sequence similarity 
to MHC-I and is predicted to consist of only the 
MHC-I α1α2 domain (42). MCMV encodes 
proteins like m144 that can associate with β2m, 
and others like m153 and m157, members of the 
m145 family, that are expressed without β2m. It is 
likely that several host genes have been captured 
by viruses during the course of coevolution (43). 
In the case of the MHC-I viral homologs it is 
probable that the closely related MHC-I genes like 
m144 and r144 were originally acquired from the 
host and that the distantly related m145 and r145 
families arose via gene duplication and expansion 
of the 144 gene shaped by the selective pressures 
of the host immune response.  
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The crystal structure of MCMV m153 
provides an example of the versatility of the 
MHC-I fold and is the first report of an obligate 
non-covalent dimer composed of two MHC-I-like 
chains. Together with the recently reported m157 
structure, it highlights both the conserved and 
divergent features of the m145 family. The m153 
monomer retains the core MHC-I characteristics, a 
β-sheet platform that supports two α-helices and 
an Ig-like α3 domain, but it exploits several 
structural adaptations to yield a stable molecule in 
the absence of peptide and β2m. Three main 
features combine to stabilize the m153 monomer: 
1) the closely spaced α1 and α2 helices on the 
platform do not form a groove and alleviate the 
need for peptide binding; 2) the extended H2b 
helix bridges the α1α2 domain to the α3 domain; 
and 3) numerous interdomain contacts and two 
unique disulfide bonds (C16-C171 and C101-
C108) stabilize the structure. Some of these 
features are shared among the other members of 
the m145 family. Whereas m157 is linked to the 
cell membrane via a glycophosphatidylinositol 
moiety and functions as a monomer (2), m153 has 
a bona fide transmembrane region and a large (47 
amino acid) intracellular domain. We have shown 
that m153 is a stable dimer when expressed in 
mammalian cells, and the crystal structure of the 
soluble ectodomain reveals the mode of 
dimerization.  
 Dimerization is unusual for MHC-I 
molecules. Although dimers of some classical 
MHC-I molecules have been reported i.e., HLA-
B27 (44) and HLA-G (45), these are disulfide-
linked and their physiological relevance remains 
unclear. A non-disulfide linked dimer has been 
observed in crystals of the rat FcRn. Unlike m153, 
the two MHC-I molecules of the FcRn interact via 
their α3 and β2m domains, utilizing extensive 
protein-protein and protein carbohydrate 
interactions at the interface (36). In the m157 
crystal, a dimer of the same orientation as m153 is 
formed with one of the symmetry related 
molecules. In m157 this dimer interface is formed 
by anti-parallel beta strand interactions between 
the β6 strand of the platform and the D strand of 
the α3 domain. Thus the same chain orientation 
but an opposite sheet of the α3 domain (ABED) is 
utilized in the observed crystal packing.  
 To gain insight into possible ligand binding 
sites on m153 we have examined regions 
corresponding to known interaction sites on 
murine MHC-I like molecules. These include the 
CD8αα binding site (α3 domain residues 220-228 
and residues of the α1α2 domain platform), the 
Ly49A NK receptor binding site (“site 2” 
including residues from the α3 domain, the α1α2 
domain platform, and key residues of β2m), and 
the region of the FcRn-Fc interaction site (N-
terminal portions of the α2 domain and of β2m) 
(7). The compact nature of the m153 dimer, its 
lack of β2m association, and the regions that are 
masked by dimerization make it unlikely that any 
of the above mentioned sites are available for 
ligand binding.    
 Since m153 is clearly related to other 
immunoevasins by both amino acid sequence and 
structure, it may be expected also to function to 
subvert the host immune response. Several 
features strongly indicate that m153 has a 
significant role in the viral life cycle. 1) Several 
regions of the m153 sequence are conserved 
among related molecules with known 
immunoregulatory function. m152 and m155 
conserve the C16-C171 disulfide, and m152 and 
m145, as well as m157, conserve the β5’-β6’ 
C101-C108 disulfide. 2) This is a readily 
expressed viral glycoprotein easily detected both 
intracellularly and at the cell surface in MCMV-
infected fibroblasts. 3) Heteroduplex mobility 
assay and DNA sequence analysis have been used 
to examine the levels of sequence variation of a 
number of MCMV genes of isolates from wild 
mice and laboratory strains. The MHC-Iv 
immunoevasins m144, m155 and m157 have 
significant variation, while m152 is highly 
conserved (17,46). m153, like m152, is highly 
conserved among many strains showing little 
variation by both heteroduplex mobility assay and 
sequencing8. Such conservation implies not only a 
role in viral survival, but suggests that m153, like 
m152, may interact with an invariant site on a host 
molecule (46). Further experiments will explore 
the identification of cellular and molecular 
ligands, and test the contribution of m153 to acute 
and chronic stages of viral infection.  
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The atomic coordinates for the crystal structure of m153 were deposited in the Research Collaboratory for 
Structural Bioinformatics Protein Databank = PDB # 2O5N 
 
8 Personal communication: Lee Smith and Alec Redwood. University of Western Australia 
 
FIGURE LEGENDS 
 
Fig. 1. m153 expression at the surface of MCMV-infected cells, β2m- and TAP-deficient cells. A. MCMV 
infected NIH3T3 cells were surface stained for m153 expression at 24 hours post infection (p.i.). Blue-
infected cells + mAb153.16, Black-infected cells + control Ab, Dashed-uninfected cells + mAb153.16. B. 
Immunoprecipitation (IP) and western blot (WB) analysis of m153 from uninfected (Lane 1) and MCMV- 
infected (Lane 2) NIH3T3 cell lysates at 24 hours p.i. IP of m153 from transfected NIH3T3 cells (IP-
mAb153.16, WB-anti-m153 rabbit serum). Samples were mock treated (Lane 3) or treated with PNGase F 
(Lane 4) before SDS-PAGE and western blot.  C. R1.1 (β2m+) and R1E (β2m-) or D. RMA (TAP+) and 
RMA-S (TAP-) cells were transfected with FLAG-m153-pIRES-GFP or H-2Dd-pIRES-GFP as a control. 
18 hours post transfection surface levels of m153 and H-2Dd were determined as described in 
Experimental Procedures. The number of GFP positive cells indicates transfection efficiency. The 
percentage surface expression is shown in the bar graphs on the right (percentage of GFP+ cells that stain 
for either FLAG-M2 or H-2Dd). 
 
Fig. 2. Conserved and unique features of the m153 monomer. A. Side view of m153 chain B. The α1, α2 
and H2b helices, the α3 domain, N- and C-termini are labeled and the disulfide bonds are in yellow. N-
terminal residues 2-20 are colored gray. B. Top view of the 7 β-strand platform and α1α2 helixes of 
m153. C. Extended N-terminus of m153 showing extensive interactions between the N-terminus (gray) 
and H2b helix, loops in the α1α2 domain and the G strand of the α3 domain (cyan). Hydrogen bonds are 
in black. D. Side view of m153 monomer. Two unique disulfide bonds link the N-terminal fragment to 
the H2b helix (C16-C171) and the β5’ platform strand to the loop connecting the β5’ and β6’ strands 
(C101-C108). Electron density around the unique disulfides is contoured at 1.25σ. The conserved 
disulfide bond (C203-255) is located in the Ig-like α3 domain.  
 
Fig. 3. Comparison of m153 with m157, H-2Kb, Rae-1β and rat neonatal FcR. A. Ribbon diagrams of the 
platform domains of m153, m157, Rae1β, FcRn and H-2Kb. The width of the groove of each molecule is 
indicated in Å and was measured at both ends and in the middle at comparable residues of the α-helices. 
B. Surface representation of the peptide-binding domain of H-2Kb (groove shown without any peptide) 
and the corresponding region of m153. Black rectangles indicate the groove.  C. Comparison of m153 
chain B with m157 and H-2Kb. The α1α2 and H2b-helices, α3-domain, and N- and C-termini are labeled. 
PDB accession codes: 2NYK, 2VAA, 1JFM and 3FRU.  
 
Fig. 4. Overall structure of the m153 dimer. A. Ribbon diagram of the m153 dimer as viewed from the 
top. Chain A - salmon, Chain B - cyan. The α1α2 helices, the α3 Ig-like domains and N- and C-termini 
are labeled. Dashed line in chain A indicates a disordered loop. Blue sticks - carbohydrates observed in 
the crystal structure, Yellow sticks - N-linked glycosylation sites confirmed by mass spectrometry.  B. 
Two 90º rotations reveal different side views of the m153 dimer, and its proposed orientation on the cell 
membrane. C. Top and bottom views of the electrostatic surface representation of the m153 dimer (red – 
acidic; blue – basic).   
 
Fig. 5. Dimer interface of m153. A. Chain A-platform/Chain B-α3 interface indicated by boxed region. B. 
Stereo view of the parallel β strand interactions between the β8’ strand of chain A (salmon) and the G 
strand of chain B (cyan). The nine hydrogen bonds are shown as black dashes. O-red, N-blue. C. 
Molecular surface representation of m153 dimer (center). At the left and right the two chains were rotated 
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75º out of the plane of the paper to display the buried interaction surfaces (white). The positions of the 
interface residues that were mutated to alanine (T128, S131, R225, S241) are shown in red. D. Mutations 
at the interface destabilize the m153 dimer. Sedimentation coefficients of wild type m153 (black – 0.3 
mg/ml) and quadruple mutant m153 (T128A, S131A, R225A, S241A, red – 0.5 mg/ml, green 0.1 mg/ml) 
as determined by sedimentation velocity ultracentrifugation.  
 
Fig. 6. m153 forms a homodimer in mammalian cells.  A. BiFC analysis. m153 constructs, fused to the N-
terminal or C-terminal portions of YFP, were cotransfected in NIH3T3 cells and the live cells were 
examined by confocal microscopy for fluorescence complementation after 48 hours. As a negative control 
YFP-fusion constructs of MCMV m144 were cotransfected. Left - YFP channel, Right - overlay of the 
YFP on the differential interference contrast (DIC) channel.  Quantification of the number of YFP 
positive cells is shown in Figure S2. B. Co-immunoprecipitation of differentially tagged m153. FLAG-
m153 (F) or F + HA-m153 (F+HA) constructs were transfected in NIH3T3 cells. 24 hours post 
transfection post-nuclear cell lysates were immunoprecipitated with anti-FLAG antibodies and detected 
on a western blot with anti-FLAG (left), anti-m153 rabbit antibodies (middle) or HA-specific antibodies 
(right).  
 
Fig. 7. Amino acid sequence alignment of the m145 family. The predicted extracellular domains of all 
m145 family members (Refseq: NC_004065 (3)) were aligned using ClustalW (47) and optimized based 
on m153 and m157 structure. Secondary structure elements of m153 are shown above and those of m157 
shown below the alignment. Cysteines involved in disulfide bonds are indicated by red (m153) and blue 
(m157) squares, and the respective pairs are indicated. Cysteines that are not conserved throughout the 
family, but are predicted to form disulfide bonds are boxed in red. Residues involved in a salt bridge (E70 
and R166) are also indicated. N-linked glycosylation sites are indicated by green stars. The residues 
involved in m153 dimer interface contacts are indicated by blue ovals. The figure was generated with 
ESPRIPT (48).  
 
LEGEND - TABLE 1 
 
aValues in parentheses are statistics for the highest resolution shell used in refinement (2.48–2.38 Å). 
bRsym(I) = ∑ | Ij - <I>| / ∑Ij, where Ij is the intensity of the jth observation of a reflection and <I> is the 
mean intensity from multiple measurements of that reflection. cRcryst = ∑ ||Fo| - |Fc|| / ∑ |Fo|, where Fo and 
Fc are the observed and calculated structure factor amplitudes, respectively. Rfree is as for Rcryst but 
calculated for a randomly selected 5.0% of reflections not included in the refinement. Procheck was used 
for model validation (49). 
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Table 1: Data collection, refinement and validation statistics 
 
Data Collection 
 
Space Group P21 
Unit cell dimensions 
    a, b, c 
    α, β, γ 
 
61.7, 78.2, 62,7 
90, 90.4, 90.0 
Molecules per asymmetric unit 2 
Resolution (Å) 2.3 
Total observations 335, 101 
Unique reflections 26, 191 
Completeness (%)a 97.5 (94.2) 
I/σI a 9.7 (2.0) 
Rsym 
a/b 0.081 (0.44) 
 
Refinement 
 
Resolution range 62.75 - 2.4 
Reflections 
    Working set 
    Test set 
 
23443 
1183 
R cryst (%)
c 23.0 
R free (%)
c 27.9 
Number of non-H protein atoms 4393 
Number of water molecules 57 
Carbohydrate chains 3 
r.m.s deviations from ideality 
    Bond lengths (Å) 
    Bond angles (deg.) 
 
0.01 
1.318 
Average B values (Å2)  
    Main-chain 
    Side-chain 
    Whole chain 
    Overall 
 A , B 
 42.2 , 32.2 
 42.5 , 32.7 
 42.4 , 32.4 
37.6 
 
Model Validation 
Ramachandran plot statistics (%) 
Procheck 
    Most favored 
    Allowed 
    Generous 
    Disallowed 
 
 
 
 
87.8 
12.2 
0 
0 
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                                                 ...                                                            m153
m153 1                                                                                             E                   M L VS I L T IV M AN  FL N V V..........EVVRPEVNRTGTVDICQGP E IFS RTSSGATGER S... KN LS S ENGGKP.GTYEWSFP ESW.........P IQ LQ REF SKYYAD VQ
m152 1                                                                                             E                   L A I L S I I VS  F Q V V.......AGSSYMDVRIFEDERVDICQD. T TFISYREGPEMFRHS N... EQ SD FR EASGEV.KHFPWMN. ELT.........Q SA FVE ERF YEYIMD FK
m17 1                                                                                             E                   I I A M T L V IT  FL Q VQNCGVSFGPDDLLADEYLTATVRSECGTI N EFY GMVLNTSEVWM G..GFDT AA FE LPNGTIN.NDVRWVN ERD.........G YK MS TEH KKFHEVWKR
m155 1                                                                                             E                   L LN I T LM I AT  I Q L V...........YIDLQDYDDDNDDYCDGLTV TIY SENSTDYVAR R...SIM FD T QDGQIT.MSCNGCPN DLG.........S LAL AN STY QTVREL GD
m151 1                                                                                             E                   V V T V L T LL V LT  FM Q L L.......................SVCESP L LTAS AGLHDAVTKT G... KQ VP T YDNGTV..CGTGWVM KDD.........P FI QG KQH SQVRG. LS
m145 1                                                                                             E                   V L LS L L T L V VT  F Q L L....SYDQRTPGDVDPECARGFEEMHHDR N TLV MLSFDVYPHF ATIA DD TSF T KWNNTPRWDHTDEGT DSYGWANDSDIPT YD FKN REF KTVRAV ME
m150 1                                                                                             E                   V L AS I L S LV I L  FL Q L L............................. A VFS IFSDSFVAGT S... ND FP R DGRGQIRDRDPSVSD KVDD.........P VH WD RFH TAFRRL GQ
m157 1                                                                                             E                   M VT I V VV VS  FL Q L.........IFNPDPDDTYIVNMDDFQFTFT EFE VTRGGVHKRT S... DNGRP VWDVGDRDPKICKICPD STD.........I YV DI KMR NNLLTQSLW
                                                 ...                                                            m157
                                                                                                                m153
m153   91                                                                                    RW                           V Y C C I I L V L I   L ATPGELV E R PVPQ...FN T THRWKGET MSFDGAIQTIRSVTSEYTTKN.EDT VKYIR....GLN TL TDNAKS EH TEICKK KD DRPDDNQYTLEDDILEDD
m152   92                                                                                    RW                           Y C C V L I I L L   IV MAGRPVVFE R KFVP...FE T LQMMDGNT TRYTVDKGVETLGSPPYSPDVSEDD ARYGR....GSG SI RDNAAL QK TSFCRK A DNPRHNEYSLYS.....N
m17   102                                                                                    RW                           C V V V V L I   VA A YAGNVTRPQDFTHIGVR..YN R SHVTVRCR KHERNFLQLVQYNRNYRNHTYPVGD GKLFESVARGVG QY DNDNSH YQ KEVCVR H SMRRYANFS ERS.....
m155   90                                                                                    RW                           L Y I L L L V   V FGP..LE E TFRLRPNNMSDYY GLWSDTCR YYNSIKNRTITYGEPKPNNCSLNDT WDADN....ARR REFLEHADD RE NATCLWN RSAKFSRLEID WYEVE...
m151   76                                                                                    RW                           V Y C C V V L V L I   IM FEAGEIS V E HLSVN..FY S KHSLNATD LYYNVGRANLISSPFDSDDGDGITS VNAFRSMASGYG FD TTHSGD RR QSICTL EKATKERSVSS SS......
m145  110                                                                                    RW                           V Y C C V L L L L   AA L FLRSRCG R E TFNATFWYG V TIVLNETV LKYNPAFVNG..TEHTLIYNKTAEK KNYAE....GRDTDL KNKVTS YP LKVYKA K GGPNSLKTR RTSN....
m150   73                                                                                    RW                           V Y C C V V L L L I   IM L FSAAVHN T E DFAPQL.VG L VHTADGTN R...SAIVTVRDKKKVVIADHSSDN TKFTT....DLD SV RRNEVS HG SSTRLK K AAPEHLEVS HVS....V
m157   93                                                                                    RW                           V Y C C V V I I   L L FDTQRIC R A LFLGFD.VI D YHTTDTVR A........YTGQTGKINIQGSGKFSTSDAK....EIGTYM KSNVRE KN RSTVQK KQ AYMNATEVE WYN.....
                 .               ........                                                                       m157
                                                                                                                m153
m153  196        C                                                                                                         M T PL Y M V L V C I S G W LIEMDIVQ Q T QV K H T WSAGRDSRAIA SADYYTDIE ASYLPVNRSQ.ILNTT E T SS ......... TVR RFSEEMVAAS.....
m152  193        C                                                                                                         M T PL Y I L M V T I S G W VRGNGYVS T R QV A N S ANGVDIYKYMR YSG..GRLK EAWLDLRDLNGS DFAFV S PT ......... YAT KYSEYPQQSP.....
m17   208        C                                                                                                         I S PA F A M M V T C T G W L..NGTVR R E PS R M G N......TPYG YTRYNYTTG SSTVNVEETN.E NST DFQ LF ........R SYE PTPGHVRGCE.....
m155  194        C                                                                                                         V S V I S W VDGRNLTK G K EGRRRMH A TD......ECGNIGYAGGRLNYTGGGFYLEAVTE APGLVCTVRTT......... LGS RNATSERVRRKSV..
m151  181        C                                                                                                         A PV M I A I N C I G W I.MTNGVV E TVSS ILW T VG...SDVQLN SSVFDNTNN SSVRAFSSVSPN SPR E ICSA ......... NVT RQPNSSAATT.....
m145  213        C                                                                                                         V T PL F I I V S C I S...NTTI E W YA Y S E EVAGLPPVKGE SKSWFTIYMRVQN..QTSDSDL KSI K R SVRGACKDVRHPRYVPPPITTSPTTTALT...
m150  174        C                                                                                                         V S PL F V V A A S C I S G W LGRHGFFC S W PA P D T RGGGLRSVSLN SRRFFSDTV LLNDFTTSSFEP DLV V R SV ......... TVT TTPSHDEAK......
m157  188        C                                                                                                         V S V F V L V C V S G W V.TTGLTT V T RSN P T E S......LNTNSSAIVTDEST DCQILTVKAPGSHAQR Y T SL ......... KGV TPPSQYRTKRVPVNI
                                                                                                                m157
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